Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04624828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

Study acronym: IOSCAR
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 24, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2023 to Jul 2026v4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 2024 to Jul 2026
    • Site details revised
    • Collaborators expanded, about 1 word
  2. Primary completion date: Dec 2022 to Dec 2023v3
  3. Primary completion date: Oct 2022 to Dec 2022
    • Study completion date: Oct 2024 to Dec 2024
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response. The hypothesis underlying this project consists in the idea that the patient's immunological context, RT and ADT may interact in the context of metastatic PC. Indeed the immune landscape of patients may interfere with the efficacy of SBRT and on the other side RT may modulate the immune response by driving immunotolerance. Scope of the study will be to investigate the immune modulation after SBRT in: * patients with diagnosis of oligorecurrence during a treatment-free interval * patients with oligoprogression or oligopersistance during hormonal therapy
Trial Details
NCT Number NCT04624828
Lead Sponsor Istituto Clinico Humanitas
Collaborators: Ipsen
Conditions
(from sponsor)		 Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov